<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01735890</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_AMV_102</org_study_id>
    <nct_id>NCT01735890</nct_id>
  </id_info>
  <brief_title>Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:

        -  To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge
           10/160mg after a single oral administration in healthy male volunteers

        -  To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis
           Exforge 10/160mg after a single oral administration in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic parameters of amlodipine and valsartan(Maximum plasma concentration (Cmax), Area under the plasma concentration curve (AUClast))</measure>
    <time_frame>Up to 144 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf, Tmax, T1/2, CL/F</measure>
    <time_frame>up to 144 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ Amlodipine/Valsartan 10/160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Novartis Exforge 10/160mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>CJ Amlodipine/Valsartan 10/160mg</arm_group_label>
    <arm_group_label>Novartis Exforge 10/160mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Years 20-45

          -  18 ≤ BMI &lt; 27kg/m²

          -  volunteer

        Exclusion Criteria:

          -  Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within
             28days prior to study medication dosing

          -  Subject with symptoms of acute disease within 28days prior to study medication dosing

          -  Subject with gastrointestinal diseases or surgery which might significantly change
             absorption of medicines

          -  Use of any prescription medication within 14 days prior to study medication dosing and
             over-the-counter medication including oriental medication within 7 days prior to study
             medication dosing

          -  Subject with known for hypersensitivity reaction to amlodipine and valsartan

          -  Subject with any of the following conditions in laboratory test i. AST(sGOT) or
             ALT(sGPT) &gt; Upper normal limit × 1.5 ii. Total bilirubin &gt; Upper normal limit × 1.5
             iii. eGFR&lt; 50mL/min ⅳ. continued serum potassium concentration abnormal status (on
             baseline visit, &lt; 3.5mEq/L or &gt; 5.5mEq/L)

          -  Positive test results for HBs Ab, HCV Ab, Syphilis regain test

          -  Drug abuse or continued excessive use of caffeine (caffeine &gt; five cups/day), severe
             heavy smoker (cigarette &gt; 10 cigarettes per day) and alcohol(alcohol&gt;30g/day)

          -  Subject who has been taken meal which affect on the absorption, distribution,
             metabolism, excretion of drug, especially grapefruit juice

          -  Clinically significant hypotension(SBP &lt; 100mmHg, DBP ≤65mmHg) or hypertension(SBP
             100mmHg, DBP &lt; 65mmHg) when screening period

          -  Participation in any clinical investigation within 60days prior to study medication
             dosing

          -  Subjects with whole blood donation within 60days, component blood donation within
             20days and blood transfusion within 30days prior to study medication dosing

          -  Subjects with decision of nonparticipation through investigator's review due to
             laboratory test results or other excuse such as non-responding to request or
             instruction by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <last_update_submitted>September 11, 2013</last_update_submitted>
  <last_update_submitted_qc>September 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

